Arm A for COVID-19
Phase-Based Progress Estimates
Effectiveness
Safety
University of California Irvine Medical Center, Orange, CA
COVID-19
NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) - DietarySupplementEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 0 Secondary · Reporting Duration: Will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy
Month 2
Change in Time to Clinical Recovery (TTCR)
Month 2
COVID Severity of Symptoms Questionnaire
Month 4
Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC)
Month 4
Change in Quality of Life Using SF-36 Survey
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm B
1 of 2
Arm A
1 of 2
Active Control
Experimental Treatment
50 Total Participants · 2 Treatment Groups
Primary Treatment: Arm A · No Placebo Group · Phase < 1
Arm A
DietarySupplement
Experimental Group · 1 Intervention: NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) · Intervention Types: DietarySupplementArm B
DietarySupplement
ActiveComparator Group · 1 Intervention: NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) · Intervention Types: DietarySupplementTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy
Trial Background
Alpesh N Amin, Principal Investigator
Principal Investigator
University of California, Irvine
Closest Location: University of California Irvine Medical Center · Orange, CA
2006First Recorded Clinical Trial
3 TrialsResearching COVID-19
42 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments